IP Law 360

JUNE 23, 2023

California federal jurors considering claims that pharmaceutical companies Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. California federal jurors considering claims that pharmaceutical companies Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd.

40

40

LexBlog IP

SEPTEMBER 16, 2021

The commercialization of FYB201 in Europe, Canada, Israel and New Zealand will be performed by Teva Pharmaceutical Industries Ltd., Boryung acquired exclusive sales rights for Onbevzi from Samsung in May of this year and, according to the company, it will become the first Avastin biosimilar available in Korea.

Licensing 52

Licensing Marketing Marketing Reporting 52

IP Tech Blog

FEBRUARY 9, 2022

Teva Pharmaceuticals USA, Inc. , In re Certain High-Potency Sweeteners was initiated by Celanese International Corporation (“Celanese”) against more than 20 respondents, including Anhui Jinhe Industrial Co., In its 2018 decision in Helsinn Healthcare S.A. and Jinhe USA LLC (collectively “Jinhe”).

Invention 57

Invention Confidentiality Public Use Patent 57

LexBlog IP

FEBRUARY 9, 2022

Teva Pharmaceuticals USA, Inc. , In re Certain High-Potency Sweeteners was initiated by Celanese International Corporation (“Celanese”) against more than 20 respondents, including Anhui Jinhe Industrial Co., In its 2018 decision in Helsinn Healthcare S.A. and Jinhe USA LLC (collectively “Jinhe”).

Invention 52

Invention Confidentiality Inventor Public Use 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Herzuma ® (Celltrion/ Teva). Truxima ® (Celltrion/Teva).

Litigation 52

Litigation Settlement Patent Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

The following tables summarize publicly available information regarding approved and select pending biosimilar Biologics License Applications (BLAs), and illustrate additional trends in the biosimilars industry. Celltrion/Teva). Celltrion/Teva). As noted above, companies are already taking advantage of these new designations.

Settlement 52

Settlement Litigation Marketing Marketing 52